Healx has raised $10 million to accelerate therapy discovery for rare diseases, including Batten disease. The company uses artificial intelligence, pharmacology expertise, and patient engagement in an effort to give those with rare diseases a better quality of life. Balderton Capital, Europe’s major…
News
A group of experts has created a set of guidelines to best manage late infantile Batten disease, also known as CLN2. Although effective strategies exist, clinicians currently lack common management guidelines to best respond to the disease’s symptoms. Multidisciplinary approaches and consensual practice guidelines are…
Researchers have found a natural model of CLN7 disease, a rare form of Batten disease, in a type of monkey called a macaque, which may prove valuable in gaining insight into the disease, as well as testing therapeutic strategies, a study reports. The study, “Discovery…
Award-winning novelist Linda Vigen Phillips has released her second young adult novel, “Behind These Hands,” about the life of a teenage girl turned upside down by a diagnosis of Batten disease. The story behind the book is based on an experience Phillips lived as a third-grade teacher, when a young boy…
Researchers have described how the CLN5 protein — the mutation of which underlies a type of Batten disease — turns into a mature soluble protein, information they hope can be used to identify new therapeutic strategies for the disease. The study, “CLN5 is cleaved by members…
Researchers have found common disease mechanisms between a type of Batten disease and a form of adult neurodegenerative disease. The study, “Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis,” was published in the journal Science Translational Medicine. Batten disease, or neuronal ceroid lipofuscinoses (NCLs), is the…
Investigational therapies now in development — especially gene and cell therapies — are reason for fresh hope among Batten disease patients and their families, according to a recent review. Substantial advances are being made, particularly regarding potential gene/cell therapies, in targeting…
Researchers have identified a previously unknown function for the CLN3 protein, whose defective form underlies juvenile Batten disease. The study, “Role of the Lysosomal Membrane Protein, CLN3, in the Regulation of Cathepsin D Activity,” was published in the Journal of Cellular Biochemistry. Neuronal ceroid lipofuscinoses (NCLs),…
The expression of two genes associated with neuronal ceroid lipofuscinosis, better known as Batten disease, was restricted to certain cells of the central nervous system in a fruit fly research model. Namely, these genes are mainly expressed in cells that form the blood brain barrier — a membrane that protects the…
Roche’s CellCept was safe, but lacked clinical benefits, during short-term use by patients with CLN3 disease, according to the results of a Phase 2 clinical trial. The study, “Short-Term Administration of Mycophenolate Is Well-Tolerated…
Recent Posts
- Many juvenile Batten disease patients face mental health issues: Study
- Our Batten disease journey carries on quietly, but with determination
- For our rare disease family, February is about love, advocacy, and unity
- Study maps juvenile Batten disease timeline, aiding care planning
- Rare disease awareness is about a brighter future for all of us
- Advocacy and communication were key to receiving quality care in a crisis
- Miglustat may slow physical decline in juvenile Batten disease: Study
- FDA clears late infantile Batten disease gene therapy for testing
- Giving thanks for every milestone as a CLN2 Batten disease parent
- Brain abnormalities can vary by age, sex in juvenile Batten